Gerald F Watts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8270935/publications.pdf

Version: 2024-02-01

738 papers	42,921 citations	2544 96 h-index	3732 179 g-index
755 all docs	755 docs citations	755 times ranked	28996 citing authors

#	Article	IF	Citations
1	The effect of Vitamin-K1 and Colchicine on Vascular Calcification Activity in subjects with Diabetes Mellitus (ViKCoVaC): A double-blind 2x2 factorial randomized controlled trial. Journal of Nuclear Cardiology, 2022, 29, 1855-1866.	2.1	17
2	Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model. Current Vascular Pharmacology, 2022, 20, 69-76.	1.7	4
3	Pilot study of universal screening of children and childâ€parent cascade testing for familial hypercholesterolaemia in Australia. Journal of Paediatrics and Child Health, 2022, 58, 281-287.	0.8	11
4	Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a doseâ€“response model. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 578-586.	3.0	14
5	The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial. American Journal of Clinical Nutrition, 2022, 115, 45-52.	4.7	14
6	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. European Heart Journal, 2022, 43, 3243-3254.	2.2	22
7	A resilient type of familial hypercholesterolaemia: caseâ€“control follow-up of genetically characterized older patients in the SAFEHEART cohort. European Journal of Preventive Cardiology, 2022, 29, 795-801.	1.8	12
8	Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiology, 2022, 18, 143-153.	1.2	13
9	Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population. Atherosclerosis, 2022, 349, 160-165.	0.8	11
10	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis, 2022, 349, 219-226.	0.8	11
11	Improving clinical practice guidelines with implementation science. Nature Reviews Cardiology, 2022, 19, 3-4.	13.7	25
12	Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nature Medicine, 2022, 28, 96-103.	30.7	128
13	APOE Îµ2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.8	16
14	Hypertriglyceridemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, Publish Ahead of Print, .	2.3	0
15	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
16	PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statinâ€treated patients with very high apolipoprotein(a) concentration. Journal of Internal Medicine, 2022, 291, 870-876.	6.0	8
17	Efficacy of probucol on cognitive function in Alzheimerâ€™s disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open, 2022, 12, e058826.	1.9	8
18	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. BioDrugs, 2022, 36, 121-135.	4.6	9

#	Article	IF	Citations
19	Population DNA screening for medically actionable disease risk in adults. Medical Journal of Australia, 2022, 216, 278-280.	1.7	10
20	Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterolâ€lowering treatments?. European Journal of Clinical Investigation, 2022, , e13766.	3.4	6
21	Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA - Journal of the American Medical Association, 2022, 327, 1679.	7.4	126
22	Microplastics, cardiometabolic risk, genetics and Alzheimer's disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 85-86.	2.3	2
23	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care. Frontiers in Genetics, 2022, 13, 905941.	2.3	11
24	Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a). American Journal of Preventive Cardiology, 2022, 10, 100343.	3.0	9
25	Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis, 2022, 349, 82-91.	0.8	26
26	A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia. Journal of Clinical Lipidology, 2022, 16, 525-529.	1.5	2
27	Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, , .	2.0	1
28	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nature Communications, 2022, 13, .	12.8	30
29	Association Between Vitamin D Supplementation and Statin-Associated Muscle Symptoms: A Systematic Review. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 337-351.	2.2	2
30	Integrated guidance to enhance the care of children and adolescents with familial hypercholesterolaemia: Practical advice for the community clinician. Journal of Paediatrics and Child Health, 2022, 58, 1297-1312.	0.8	6
31	The Inherited Hypercholesterolemias. Endocrinology and Metabolism Clinics of North America, 2022, 51, 511-537.	3.2	5
32	Predicting resilience in heterozygous familial hypercholesterolaemia: a cohort study of octogenarian patients. Journal of Clinical Lipidology, 2022, , .	1.5	1
33	¹⁸ F-Sodium Fluoride Positron Emission Tomography Activity Predicts the Development of New Coronary Artery Calcifications. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 534-541.	2.4	14
34	Practical Guidance for Food Consumption to Prevent Cardiovascular Disease. Heart Lung and Circulation, 2021, 30, 163-179.	0.4	22
35	Lipoprotein apheresis and <scp>PCSK9</scp> inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. Journal of Clinical Apheresis, 2021, 36, 48-58.	1.3	5
36	Increased risk of 2-year death in patients who discontinued their use of statins. Journal of Health Services Research and Policy, 2021, 26, 95-105.	1.7	1

#	Article	IF	Citations
37	Lipoprotein(a) in Patients With Type 2 Diabetes and Premature Coronary Artery Disease in the Coronary Care Unit. Heart Lung and Circulation, 2021, 30, 734-740.	0.4	5
38	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung and Circulation, 2021, 30, 324-349.	0.4	51
39	Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158869.	2.4	7
40	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. Pathology, 2021, 53, 288-290.	0.6	0
41	Under-Reporting of Family History of Premature Coronary Artery Disease in Patients Discharged From Coronary Care: Implications for the Detection of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2021, 30, e48-e49.	0.4	0
42	Validity and reliability of an adapted questionnaire measuring knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia. BMC Cardiovascular Disorders, 2021, 21, 39.	1.7	7
43	Editorial: Dyslipidaemia and cardiometabolic health: springboard for an emerging medical specialty?. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 83-84.	2.3	0
44	Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. European Heart Journal, 2021, 42, 2201-2211.	2.2	33
45	Evaluation of Transthoracic Echocardiography in the Assessment of Atherosclerosis of the Left Main Coronary Artery: Comparison with Optical Frequency Domain Imaging (a Pilot Study). Journal of Clinical Medicine, 2021, 10, 256.	2.4	1
46	Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance. Cardiovascular Drugs and Therapy, 2021, 35, 841-852.	2.6	7
47	New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects. Frontiers in Physiology, 2021, 12, 603910.	2.8	10
48	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. Heart Lung and Circulation, 2021, 30, 372-379.	0.4	14
49	Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. Current Opinion in Cardiology, 2021, 36, 272-280.	1.8	12
50	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis, 2021, 320, 1-9.	0.8	11
51	Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. Internal Medicine Journal, 2021, 51, 769-779.	0.8	4
52	A compass for navigating the perils of hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2021, 9, 248-249.	11.4	1
53	Effectiveness of proprotein convertase subtilisin/kexinâ€9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic. Clinical Cardiology, 2021, 44, 805-813.	1.8	7
54	Evolving worldwide approaches to lipid management and implications for Australian general practice. Australian Journal of General Practice, 2021, 50, 297-304.	0.8	5

#	Article	IF	Citations
55	Improving detection and management of familial hypercholesterolaemia in Australian general practice. Heart, 2021, 107, 1213-1219.	2.9	13
56	Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. American Journal of Preventive Cardiology, 2021, 6, 100151.	3.0	3
57	Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a FamilyÂHistory of Coronary Disease. JACC: Cardiovascular Imaging, 2021, 14, 1206-1217.	5.3	18
58	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. BMC Infectious Diseases, 2021, 21, 580.	2.9	20
59	Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management. Current Opinion in Lipidology, 2021, 32, 210-212.	2.7	3
60	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart, 2021, 8, e001710.	2.3	1
61	Awareness of familial hypercholesterolaemia in Australian primary care: A qualitative descriptive study. Australian Journal of General Practice, 2021, 50, 634-640.	0.8	2
62	The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. Current Medicinal Chemistry, 2021, 28, 6066-6081.	2.4	6
63	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	3.3	1
64	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
65	Ankylosing Spondylitis and Risk of Cardiac Arrhythmia and Conduction Disorders: A Systematic Review and Meta-analysis. Current Cardiology Reviews, 2021, 17, e150521193326.	1.5	5
66	Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners. Australian Journal of General Practice, 2021, 50, 616-621.	0.8	3
67	Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase. Research in Social and Administrative Pharmacy, 2021, 17, 1780-1785.	3.0	1
68	Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. Atherosclerosis, 2021, 334, 57-65.	0.8	7
69	Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacological Research, 2021, 173, 105812.	7.1	39
70	Unravelling lipoprotein metabolism with stable isotopes: tracing the flow. Metabolism: Clinical and Experimental, 2021, 124, 154887.	3.4	7
71	Lipoprotein (a) and diabetes mellitus: causes and consequences. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 181-187.	2.3	13
72	Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a). Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 174-180.	2.3	4

#	Article	IF	Citations
73	Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies. Current Opinion in Lipidology, 2021, 32, 378-385.	2.7	3
74	Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations. Current Opinion in Lipidology, 2021, Publish Ahead of Print, 355-362.	2.7	1
75	Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel. Journal of Clinical Medicine, 2021, 10, 4930.	2.4	10
76	Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 104-113.	2.3	2
77	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. Contemporary Cardiology, 2021, , 615-636.	0.1	0
78	Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities. Clinical Chemistry, 2021, 67, 6-8.	3.2	0
79	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
80	Lipoprotein (a) and Hypertension. Current Hypertension Reports, 2021, 23, 44.	3.5	10
81	Recent advances in synthetic pharmacotherapies for dyslipidaemias. European Journal of Preventive Cardiology, 2020, 27, 1576-1596.	1.8	24
82	A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. Drug Discovery Today, 2020, 25, 58-72.	6.4	27
83	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. Clinical Genetics, 2020, 97, 257-263.	2.0	7
84	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. JAMA Cardiology, 2020, 5, 217.	6.1	169
85	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 2020, 10, 106.	3.3	41
86	Familial Hypercholesterolaemia in 2020: AÂLeading Tier 1 Genomic Application. Heart Lung and Circulation, 2020, 29, 619-633.	0.4	22
87	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clinical Chemistry and Laboratory Medicine, 2020, 58, 496-517.	2.3	119
88	Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?. Clinical Genetics, 2020, 97, 543-555.	2.0	6
89	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism: Clinical and Experimental, 2020, 113, 154375.	3.4	40
90	High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biology, 2020, 18, e3000870.	5.6	89

#	Article	IF	Citations
91	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. Clinica Chimica Acta, 2020, 510, 211-215.	1.1	11
92	The economic impact of familial hypercholesterolemia on productivity. Journal of Clinical Lipidology, 2020, 14, 799-806.e3.	1.5	11
93	Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids in Health and Disease, 2020, 19, 239.	3.0	12
94	Coronary artery calcium scoring in cardiovascular risk assessment of people with family histories of early onset coronary artery disease. Medical Journal of Australia, 2020, 213, 170-177.	1.7	17
95	The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2020, 22, 64.	4.8	24
96	Mental health recovery and physical health outcomes in psychotic illness: Longitudinal data from the Western Australian survey of high impact psychosis catchments. Australian and New Zealand Journal of Psychiatry, 2020, 55, 000486742095426.	2.3	13
97	Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods. Current Opinion in Lipidology, 2020, 31, 347-355.	2.7	17
98	Atherogenic Dyslipoproteinemia and Management of ASCVD. Journal of the American College of Cardiology, 2020, 75, 2136-2139.	2.8	3
99	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. Atherosclerosis, 2020, 304, 1-8.	0.8	36
100	Metabolism of lipoprotein(a). Current Opinion in Lipidology, 2020, 31, 163-165.	2.7	3
101	Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease. Circulation, 2020, 141, 1742-1759.	1.6	301
102	Familial Hypercholesterolemia in a Healthy Elderly Population. Circulation Genomic and Precision Medicine, 2020, 13, e002938.	3.6	8
103	The brave new world of genetic testing in the management of the dyslipidaemias. Current Opinion in Cardiology, 2020, 35, 226-233.	1.8	10
104	Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. Journal of the American Heart Association, 2020, 9, e015355.	3.7	30
105	Familial hypercholesterolaemia and COVIDâ€19: triggering of increased sustained cardiovascular risk. Journal of Internal Medicine, 2020, 287, 746-747.	6.0	46
106	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020, 298, 52-57.	0.8	14
107	Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study. Journal of Lipid Research, 2020, 61, 537-545.	4.2	29
108	Long-Term Evolocumab in Patients With FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 565-574.	2.8	126

#	Article	IF	Citations
109	Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nature Reviews Cardiology, 2020, 17, 360-377.	13.7	82
110	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis, 2020, 294, 46-61.	0.8	137
111	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology, 2020, 52, 447-452.	0.6	3
112	PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a). Metabolism: Clinical and Experimental, 2020, 107, 154221.	3.4	46
113	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atherosclerosis Supplements, 2020, 42, e30-e34.	1.2	6
114	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	2.2	776
115	Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia. Circulation, 2020, 142, .	1.6	29
116	Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study. Public Health Research and Practice, 2020, 30, .	1.5	5
117	Familial hypercholesterolaemia and cascade testing in general practice: Lessons from COVID-19. Australian Journal of General Practice, 2020, 49, 859-860.	0.8	1
118	Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia. Circulation, 2020, 142, .	1.6	8
119	Relationship between pulse pressure and inflammation with left ventricular diastolic dysfunction in chronic kidney disease patients. Internal Medicine Journal, 2019, 49, 240-247.	0.8	2
120	Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome. Diabetic Medicine, 2019, 36, 1643-1651.	2.3	16
121	Homozygous familial hypercholesterolaemia in childhood â€“ The first case report in Southeast Europe. Atherosclerosis Supplements, 2019, 40, 122-124.	1.2	2
122	A web-based registry for rare genetic lipid disorders. Pathology, 2019, 51, S108.	0.6	0
123	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. Clinical Chemistry, 2019, 65, 1258-1266.	3.2	37
124	Vulnerabilities in diabetic eye screening for children and young people in England. Pediatric Diabetes, 2019, 20, 932-940.	2.9	2
125	A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. Journal of Clinical Lipidology, 2019, 13, 608-617.	1.5	22
126	Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study. Social Science and Medicine, 2019, 242, 112591.	3.8	13

#	Article	IF	Citations
127	Identifying Perceptions and Preferences of the General Public Concerning Universal Screening of Children for Familial Hypercholesterolaemia. Public Health Genomics, 2019, 22, 25-35.	1.0	13
128	Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6247-6255.	3.6	16
129	A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research, 2019, 150, 104413.	7.1	70
130	PCSK9 inhibition 2018: riding a new wave of coronary prevention. Clinical Science, 2019, 133, 205-224.	4.3	8
131	Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies. Journal of Clinical Medicine, 2019, 8, 118.	2.4	48
132	Statin Toxicity. Circulation Research, 2019, 124, 328-350.	4.5	439
133	Response by Ward et al to Letter Regarding Article, â€œStatin Toxicity: Mechanistic Insights and Clinical Implicationsâ€• Circulation Research, 2019, 124, e121-e122.	4.5	18
134	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
135	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. Journal of Clinical Lipidology, 2019, 13, 580-585.	1.5	16
136	Residual vascular risk in diabetes â€“ Will the SPPARM alpha concept hold the key?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 2723-2725.	3.6	4
137	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. Current Vascular Pharmacology, 2019, 17, 538-540.	1.7	23
138	Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 286, 40-45.	0.8	7
139	Status of PCSK9 Monoclonal Antibodies in Australia. Heart Lung and Circulation, 2019, 28, 1571-1579.	0.4	9
140	Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. Metabolism: Clinical and Experimental, 2019, 96, 8-11.	3.4	10
141	Whatâ€™s new on therapies for elevated lipoprotein(a). Expert Review of Clinical Pharmacology, 2019, 12, 495-499.	3.1	0
142	Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. Diabetes, Obesity and Metabolism, 2019, 21, 52-62.	4.4	10
143	A window into the heart of familial hypercholesterolaemia in the community. Lancet Public Health, The, 2019, 4, e216-e217.	10.0	2
144	Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterolâ€Lowering Therapy. Journal of the American Heart Association, 2019, 8, e011781.	3.7	40

#	Article	IF	Citations
145	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 143, 1-16.	7.1	90
146	Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it. Diabetes, Obesity and Metabolism, 2019, 21, 1734-1736.	4.4	6
147	Value of Measuring Lipoprotein(a) DuringÂCascade Testing for FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2019, 73, 1029-1039.	2.8	99
148	PCSK9 in HIV infection: New opportunity or red herring?. Atherosclerosis, 2019, 284, 216-217.	0.8	2
149	To test, or not to test: that is the question for the future of lipoprotein(a). Expert Review of Cardiovascular Therapy, 2019, 17, 241-250.	1.5	4
150	PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. European Journal of Preventive Cardiology, 2019, 26, 998-1000.	1.8	11
151	Comparative aspects of the care of familial hypercholesterolemia in the â€œTen Countries Studyâ€• Journal of Clinical Lipidology, 2019, 13, 287-300.	1.5	32
152	The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients. , 2019, 29, 377-385.		6
153	Lipid management in people with peripheral artery disease. Current Opinion in Lipidology, 2019, 30, 470-476.	2.7	19
154	Editorial. Current Opinion in Lipidology, 2019, 30, 417-418.	2.7	0
155	Familial Hypercholesterolaemia Registry in the MENA Region. Current Vascular Pharmacology, 2019, 18, 65-67.	1.7	0
156	Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?. Journal of Clinical Medicine, 2019, 8, 2073.	2.4	15
157	Loneliness in psychotic illness and its association with cardiometabolic disorders. Schizophrenia Research, 2019, 204, 90-95.	2.0	20
158	Improving the detection of familial hypercholesterolaemia. Pathology, 2019, 51, 213-221.	0.6	13
159	Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 281, 25-30.	0.8	31
160	Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH. Atherosclerosis, 2019, 281, 145-147.	0.8	1
161	Dyslipidaemia in adults with type 1 diabetesâ€”when to treat?. Diabetes/Metabolism Research and Reviews, 2019, 35, e3090.	4.0	7
162	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. Current Vascular Pharmacology, 2019, 17, 515-537.	1.7	19

#	Article	IF	Citations
163	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Current Vascular Pharmacology, 2019, 17, 498-514.	1.7	38
164	Editorial: Familial Hypercholesterolaemia Registry in the MENA Region. Current Vascular Pharmacology, 2019, , 1.	1.7	0
165	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clinical Cardiology, 2018, 41, 378-384.	1.8	36
166	Parentâ€“child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of Paediatrics and Child Health, 2018, 54, 741-747.	0.8	18
167	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1704-1714.	3.6	41
168	Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?. Cardiology Clinics, 2018, 36, 287-298.	2.2	13
169	Nutraceuticals in the management of patients with statinâ€associated muscle symptoms, with a note on realâ€world experience. Clinical Cardiology, 2018, 41, 159-165.	1.8	24
170	Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. Journal of Clinical Lipidology, 2018, 12, 1019-1026.	1.5	28
171	Health literacy in familial hypercholesterolemia: A cross-national study. European Journal of Preventive Cardiology, 2018, 25, 936-943.	1.8	36
172	The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. Prostaglandins and Other Lipid Mediators, 2018, 136, 1-8.	1.9	41
173	Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. European Heart Journal, 2018, 39, 2577-2585.	2.2	116
174	Counting up the risks: How common are risk factors for morbidity and mortality in young people with psychosis?. Microbial Biotechnology, 2018, 12, 1045-1051.	1.7	7
175	PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Diabetes, Obesity and Metabolism, 2018, 20, 270-282.	4.4	22
176	Rationale and design of a trial to personalize risk assessment in familial coronary artery disease. American Heart Journal, 2018, 199, 22-30.	2.7	14
177	Acute Impact of Different Exercise Modalities on Arterial and Platelet Function. Medicine and Science in Sports and Exercise, 2018, 50, 785-791.	0.4	4
178	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs, 2018, 78, 99-109.	10.9	36
179	Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 433-435.	2.7	0
180	Lipoprotein (a) and Lowâ€density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. European Journal of Clinical Investigation, 2018, 49, e13053.	3.4	11

#	Article	IF	Citations
181	Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific Reports, 2018, 8, 17887.	3.3	48
182	Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part. Atherosclerosis, 2018, 277, 399-406.	0.8	38
183	Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice. Atherosclerosis, 2018, 277, 470-476.	0.8	6
184	Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families. Atherosclerosis, 2018, 277, 392-398.	0.8	11
185	Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training. Atherosclerosis, 2018, 277, 508-516.	0.8	14
186	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.8	163
187	Improving the global care of familial hypercholesterolaemia: Starting the ball rolling. Atherosclerosis, 2018, 277, 230-233.	0.8	7
188	MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy. Trends in Pharmacological Sciences, 2018, 39, 967-981.	8.7	48
189	Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. Atherosclerosis, 2018, 277, 493-501.	0.8	18
190	Lipoprotein(a): lodestar for future clinical trials. Lancet, The, 2018, 392, 1281-1282.	13.7	10
191	Introducing the â€˜Druceboâ€™ effect in statin therapy: a systematic review of studies comparing reported rates of statinâ€associated muscle symptoms, under blinded and openâ€label conditions. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1023-1033.	7.3	84
192	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. Journal of Clinical Lipidology, 2018, 12, 1358-1366.	1.5	30
193	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. European Heart Journal, 2018, 39, 3635-3640.	2.2	25
194	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clinical Chemistry, 2018, 64, 1006-1033.	3.2	189
195	Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy. Diabetes Research and Clinical Practice, 2018, 141, 156-167.	2.8	4
196	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
197	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. Current Atherosclerosis Reports, 2018, 20, 31.	4.8	19
198	PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. Journal of Clinical Lipidology, 2018, 12, 844-848.	1.5	1

#	Article	IF	Citations
199	Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque. Atherosclerosis, 2018, 275, 232-238.	0.8	21
200	The Role of Nutraceuticals in StatinÂIntolerant Patients. Journal of the American College of Cardiology, 2018, 72, 96-118.	2.8	216
201	In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratification. Journal of Nuclear Cardiology, 2018, 25, 1774-1783.	2.1	32
202	Squaring up the health economics of PCSK9 monoclonal antibodies â€˜down underâ€™. International Journal of Cardiology, 2018, 267, 193-194.	1.7	3
203	Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1644-1655.	2.4	30
204	The impact of nonâ€vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia. Medical Journal of Australia, 2018, 208, 18-23.	1.7	9
205	Insulin resistance and vascular dysfunction in chronic kidney disease: mechanisms and therapeutic interventions. Nephrology Dialysis Transplantation, 2017, 32, gfv326.	0.7	14
206	Cytomegalovirus antibody and vascular pathology in renal transplant recipients. Journal of Medical Virology, 2017, 89, 177-181.	5.0	18
207	A Web-Based Registry for Familial Hypercholesterolaemia. Heart Lung and Circulation, 2017, 26, 635-639.	0.4	16
208	Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 260-271.	1.5	87
209	Detecting familial hypercholesterolemia: The Jack and the Beanstalk principle. Journal of Clinical Lipidology, 2017, 11, 575-578.	1.5	4
210	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes and Endocrinology,the, 2017, 5, 280-290.	11.4	191
211	Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Medicine, 2017, 15, 22.	5.5	65
212	Predicting Cardiovascular Events in Familial Hypercholesterolemia. Circulation, 2017, 135, 2133-2144.	1.6	270
213	Personal modelâ€assisted identification of NAD⁺ andÂglutathione metabolism as intervention target in NAFLD. Molecular Systems Biology, 2017, 13, 916.	7.2	147
214	Novel protein biomarkers associated with coronary artery disease in statin-treated patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 682-693.	1.5	28
215	Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. Clinical Science, 2017, 131, 791-797.	4.3	5
216	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	2.2	2,292

#	Article	IF	Citations
217	New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. European Journal of Preventive Cardiology, 2017, 24, 1200-1205.	1.8	14
218	Toward an international consensusâ€"Integrating lipoprotein apheresis and new lipid-lowering drugs. Journal of Clinical Lipidology, 2017, 11, 858-871.e3.	1.5	105
219	Beyond cascade screening: detection of familial hypercholesterolaemia at childhood immunization and other strategies. Current Opinion in Lipidology, 2017, 28, 321-327.	2.7	15
220	Mode of action of berberine on lipid metabolism: a newâ€"old phytochemical with clinical applications?. Current Opinion in Lipidology, 2017, 28, 282-283.	2.7	12
221	Increasing the Detection of Familial Hypercholesterolaemia Using General Practice Electronic Databases. Heart Lung and Circulation, 2017, 26, 450-454.	0.4	29
222	Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management. Atherosclerosis, 2017, 263, 112-118.	0.8	4
223	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. Current Hypertension Reports, 2017, 19, 30.	3.5	3
224	Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study. Atherosclerosis, 2017, 256, 62-66.	0.8	23
225	The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis. Schizophrenia Research, 2017, 184, 88-95.	2.0	2
226	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation, 2017, 135, 338-351.	1.6	80
227	Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a). European Heart Journal, 2017, 38, 3555-3559.	2.2	21
228	The shape of things to come in lipid management: a feast of reason. Current Opinion in Lipidology, 2017, 28, 449-451.	2.7	0
229	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 2017, 68, 57-82.	11.6	63
230	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Current Opinion in Lipidology, 2017, 28, 495-501.	2.7	31
231	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. Circulation, 2017, 136, 1878-1891.	1.6	144
232	The evolving model of care for familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2017, 24, 1729-1732.	1.8	4
233	Knowns and unknowns in the care of pediatric familial hypercholesterolemia. Journal of Lipid Research, 2017, 58, 1765-1776.	4.2	39
234	Reverse cascade screening for familial hypercholesterolemia in highâ€risk Chinese families. Clinical Cardiology, 2017, 40, 1169-1173.	1.8	13

#	Article	IF	Citations
235	An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the â€œTen Countries Studyâ€• BMJ Open, 2017, 7, e017817.	1.9	33
236	Lipoprotein apheresis downregulates IL-1Î±, IL-6 and TNF-Î± mRNA expression in severe dyslipidaemia. Atherosclerosis Supplements, 2017, 30, 200-208.	1.2	16
237	The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. Current Hypertension Reports, 2017, 19, 99.	3.5	16
238	Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. BMJ Open, 2017, 7, e013691.	1.9	1
239	Response by Watts et al to Letter Regarding Article, â€œFactorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolismâ€• Circulation, 2017, 136, 120-121.	1.6	0
240	Effect of Alirocumab on Lipoprotein(a) Over â‰¥1.5ÂYears (from the Phase 3 ODYSSEY Program). American Journal of Cardiology, 2017, 119, 40-46.	1.6	116
241	The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis. Schizophrenia Research, 2017, 182, 13-18.	2.0	3
242	Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2017, 24, 133-136.	1.8	9
243	Optimizing Cholesterol Treatment in Patients With Muscle Complaints. Journal of the American College of Cardiology, 2017, 70, 1290-1301.	2.8	162
244	Comprehending the Health Informatics Spectrum: Grappling with System Entropy and Advancing Quality Clinical Research. Frontiers in Public Health, 2017, 5, 224.	2.7	2
245	Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration. Journal of Atherosclerosis and Thrombosis, 2017, 24, 1075-1084.	2.0	29
246	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	2.3	30
247	Detection and management of familial hypercholesterolaemia in primary care in Australia: protocol for a pragmatic cluster intervention study with pre-post intervention comparisons. BMJ Open, 2017, 7, e017539.	1.9	8
248	International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?. Journal of Atherosclerosis and Thrombosis, 2016, 23, 505-519.	2.0	29
249	Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	9
250	Progress in the care of familial hypercholesterolaemia: 2016. Medical Journal of Australia, 2016, 205, 232-236.	1.7	15
251	Translational Research for Improving the Care of Familial Hypercholesterolemia: The â€œTen Countries Studyâ€•and Beyond. Journal of Atherosclerosis and Thrombosis, 2016, 23, 891-900.	2.0	36
252	MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 878-883.	2.0	21

#	Article	IF	Citations
253	n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. Nutrients, 2016, 8, 175.	4.1	32
254	Management of Familial Hypercholesterolemia in Hong Kong. Journal of Atherosclerosis and Thrombosis, 2016, 23, 520-531.	2.0	10
255	The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thrombosis and Haemostasis, 2016, 115, 520-532.	3.4	138
256	Risk Factors for Obstructive Sleep Apnea Are Prevalent in People with Psychosis and Correlate with Impaired Social Functioning and Poor Physical Health. Frontiers in Psychiatry, 2016, 7, 139.	2.6	15
257	Correlates of physical activity in people living with psychotic illness. Acta Psychiatrica Scandinavica, 2016, 134, 129-137.	4.5	44
258	Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men. Physiological Reports, 2016, 4, e12951.	1.7	3
259	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atherosclerosis Supplements, 2016, 22, 1-32.	1.2	90
260	ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?. European Heart Journal, 2016, 37, 3596-3599.	2.2	13
261	An online questionnaire survey of UK general practitionersâ€™ knowledge and management of familial hypercholesterolaemia. BMJ Open, 2016, 6, e012691.	1.9	25
262	Challenges in the health economics of familial hypercholesterolemia. Current Opinion in Lipidology, 2016, 27, 563-569.	2.7	9
263	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpointsâ€"A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry, 2016, 62, 930-946.	3.2	145
264	Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. Journal of Clinical Lipidology, 2016, 10, 1188-1194.	1.5	14
265	Metabolic syndrome in people with a psychotic illness: is cannabis protective?. Psychological Medicine, 2016, 46, 1651-1662.	4.5	20
266	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	9.6	28
267	Interpreting Community-Based Enterprise: A Case Study from Rural Wales. Journal of Social Entrepreneurship, 2016, 7, 211-235.	2.5	22
268	Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. Schizophrenia Bulletin, 2016, 42, 1280-1289.	4.3	9
269	Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes. Heart Lung and Circulation, 2016, 25, 1051-1054.	0.4	0
270	Under-Recognised and Underestimated: The Cardiovascular Health Burden of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2016, 25, 1045-1047.	0.4	1

#	Article	IF	Citations
271	Author reply. Internal Medicine Journal, 2016, 46, 863-863.	0.8	0
272	Effect of omega-3 fatty acid supplementation on arterial elasticity in patients with familial hypercholesterolaemia on statin therapy. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1140-1145.	2.6	19
273	Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin. Atherosclerosis, 2016, 252, 82-87.	0.8	12
274	Statin therapy and plasma free fatty acids: a systematic review and metaâ€analysis of controlled clinical trials. British Journal of Clinical Pharmacology, 2016, 81, 807-818.	2.4	39
275	The association between chronic hepatitis C infection and cardiovascular risk. Internal Medicine Journal, 2016, 46, 63-70.	0.8	14
276	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. Journal of Clinical Lipidology, 2016, 10, 1329-1337.e3.	1.5	46
277	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. Pathology, 2016, 48, 463-466.	0.6	13
278	Ï‰-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3732-3739.	3.6	29
279	Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities. Journal of Clinical Lipidology, 2016, 10, 1278-1279.	1.5	5
280	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
281	Triglycerideâ€rich lipoprotein metabolism in women: roles of apoCâ€<scp>II</scp> and apoCâ€<scp>III</scp>. European Journal of Clinical Investigation, 2016, 46, 730-736.	3.4	9
282	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Scientific Reports, 2016, 6, 30060.	3.3	25
283	A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice. Heart, 2016, 102, 855-861.	2.9	50
284	Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism. Current Opinion in Lipidology, 2016, 27, 550-556.	2.7	5
285	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-pointsâ€"a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 2016, 37, 1944-1958.	2.2	542
286	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes and Endocrinology,the, 2016, 4, 850-861.	11.4	329
287	Developing role of microRNA-33 in lipid metabolism and atherosclerosis. Current Opinion in Lipidology, 2016, 27, 197-199.	2.7	7
288	Effect of niacin on triglycerideâ€rich lipoprotein apolipoprotein Bâ€48 kinetics in statinâ€treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 384-391.	4.4	10

#	Article	IF	Citations
289	A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clinical Nutrition, 2016, 35, 331-336.	5.0	55
290	ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1398-1406.	3.6	4
291	Dyslipidemia in Obesity. , 2016, , 525-540.		4
292	Attainment of LDL-Cholesterol TreatmentÂGoals in Patients With FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2016, 67, 1278-1285.	2.8	221
293	Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. European Heart Journal, 2016, 37, 1384-1394.	2.2	326
294	Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?. European Heart Journal, 2016, 37, 1353-1356.	2.2	14
295	Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors. International Journal of Behavioral Medicine, 2016, 23, 282-294.	1.7	38
296	Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. Heart Lung and Circulation, 2016, 25, 520-525.	0.4	50
297	Prevalence of Familial Hypercholesterolemia in Adolescents: Potential Value of Universal Screening?. Journal of Pediatrics, 2016, 170, 315-316.	1.8	55
298	Common familial risk factors for schizophrenia and diabetes mellitus. Australian and New Zealand Journal of Psychiatry, 2016, 50, 488-494.	2.3	21
299	Diabetes, statins and FH. International Journal of Cardiology, 2016, 203, 575.	1.7	2
300	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1290-1297.	2.8	49
301	Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action. Australian Prescriber, 2016, 39, 164-167.	1.0	55
302	Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pharmaceutical Design, 2016, 22, 595-608.	1.9	12
303	Knowledge and Awareness of Familial Hypercholesterolaemia among Registered Medical Practitioners in Tamil Nadu: Are They Suboptimal?. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, OC52-6.	0.8	9
304	Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. Journal of Clinical Lipidology, 2015, 9, 703-708.	1.5	75
305	Association between statin use and plasma D-dimer levels. Thrombosis and Haemostasis, 2015, 114, 546-557.	3.4	127
306	n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease. Journal of Hypertension, 2015, 33, 1947-1953.	0.5	23

#	Article	IF	Citations
307	Screening for familial hypercholesterolemia: primary care applications. Clinical Lipidology, 2015, 10, 295-298.	0.4	2
308	The hinterland of familial hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 475-483.	2.7	6
309	Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?. Expert Review of Clinical Pharmacology, 2015, 8, 363-366.	3.1	6
310	Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis, 2015, 241, 769-771.	0.8	7
311	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. European Journal of Preventive Cardiology, 2015, 22, 849-854.	1.8	60
312	The Agenda for Familial Hypercholesterolemia. Circulation, 2015, 132, 2167-2192.	1.6	539
313	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2218-2224.	2.4	58
314	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics, 2015, 37, 2732-2750.	2.5	7
315	Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: A pilot study. Journal of Clinical Lipidology, 2015, 9, 42-48.	1.5	42
316	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015, 239, 93-100.	0.8	65
317	Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample. Australian and New Zealand Journal of Psychiatry, 2015, 49, 714-723.	2.3	11
318	Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. AAPS PharmSciTech, 2015, 16, 45-52.	3.3	47
319	Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update. Nutrients, 2015, 7, 4416-4425.	4.1	101
320	Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy. Atherosclerosis, 2015, 242, 295-302.	0.8	19
321	Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis, 2015, 242, 226-229.	0.8	28
322	Statin therapy and plasma coenzyme Q10 concentrationsâ€"A systematic review and meta-analysis of placebo-controlled trials. Pharmacological Research, 2015, 99, 329-336.	7.1	145
323	Inter-relationships between proprotein convertase subtilisin/kexin typeÂ9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state. Clinical Science, 2015, 128, 379-385.	4.3	39
324	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin typeÂ9. Clinical Science, 2015, 129, 63-79.	4.3	21

#	Article	IF	Citations
325	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3140-3148.	3.6	198
326	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis, 2015, 242, 87-96.	0.8	47
327	Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2497-2501.	3.6	24
328	Prevalence and treatment of familial hypercholesterolaemia in Australian communities. International Journal of Cardiology, 2015, 185, 69-71.	1.7	66
329	Systematic Detection of Familial Hypercholesterolaemia in Primary Health Care: A Community Based Prospective Study of Three Methods. Heart Lung and Circulation, 2015, 24, 250-256.	0.4	42
330	Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials. Atherosclerosis, 2015, 240, 284-296.	0.8	11
331	Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein. Circulation Research, 2015, 116, 193-205.	4.5	58
332	Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opinion on Emerging Drugs, 2015, 20, 299-312.	2.4	6
333	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	2.2	644
334	Familial hypercholesterolaemia: A global call to arms. Atherosclerosis, 2015, 243, 257-259.	0.8	148
335	Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry,the, 2015, 2, 1092-1098.	7.4	22
336	Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (<scp>PCSK9</scp>) concentrations: a systematic review and metaâ€analysis of clinical trials. Diabetes, Obesity and Metabolism, 2015, 17, 1042-1055.	4.4	77
337	Dyslipidemia in Obesity. , 2015, , 1-18.		1
338	Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia. Drugs, 2015, 75, 1715-1724.	10.9	44
339	Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women. Journal of the American Heart Association, 2015, 4, e002258.	3.7	44
340	Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. International Journal of Cardiology, 2015, 201, 79-84.	1.7	32
341	Statins and Mipomersen: Mechanisms of Action and Patient Tolerability. , 2015, , 73-86.		1
342	Challenges in the care of familial hypercholesterolemia: a community care perspective. Expert Review of Cardiovascular Therapy, 2015, 13, 1091-1100.	1.5	13

#	Article	IF	Citations
343	Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1505-1515.	3.3	11
344	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2015, 201, 633-638.	1.7	66
345	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. Clinica Chimica Acta, 2015, 448, 18-21.	1.1	13
346	Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100â€“Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2686-2693.	2.4	45
347	Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10?. Current Atherosclerosis Reports, 2015, 17, 472.	4.8	32
348	Patientsâ€™ Perceptions and Experiences of Familial Hypercholesterolemia, Cascade Genetic Screening and Treatment. International Journal of Behavioral Medicine, 2015, 22, 92-100.	1.7	63
349	Sorting the Wheat from the Chaff in Familial Hypercholesterolemia. Clinical Chemistry, 2015, 61, 6-8.	3.2	0
350	Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet, The, 2015, 385, 307-310.	13.7	29
351	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development and Therapy, 2014, 8, 1221.	4.3	32
352	An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	4.3	27
353	Managing recalcitrant hypercholesterolemia in patients on current best standard of care: efficacy and safety of novel pharmacotherapies. Clinical Lipidology, 2014, 9, 221-233.	0.4	10
354	Effect of Ï‰-3 Fatty Acid Ethyl Esters on Apolipoprotein B-48 Kinetics in Obese Subjects on a Weight-Loss Diet: A New Tracer Kinetic Study in the Postprandial State. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1427-E1435.	3.6	26
355	Dose-Dependent Effects of Rosuvastatin on the Plasma Sphingolipidome and Phospholipidome in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2335-E2340.	3.6	59
356	Effect of Niacin on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Statin-Treated Patients With Type 2 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 427-432.	2.4	28
357	A framework for bridging the gap in the care of familial hypercholesterolaemia in the community. International Journal of Evidence-Based Healthcare, 2014, 12, 244-254.	0.5	2
358	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	2.2	835
359	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemannâ€“Pick disease type B presenting to a lipid disorders clinic. Annals of Clinical Biochemistry, 2014, 51, 615-618.	1.6	3
360	Interrelationships Between the Kinetics of VLDL Subspecies and HDL Catabolism in Abdominal Obesity: A Multicenter Tracer Kinetic Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4281-4290.	3.6	22

#	Article	IF	Citations
361	Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis. World Psychiatry, 2014, 13, 176-183.	10.4	30
362	Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services. Heart Lung and Circulation, 2014, 23, 1158-1164.	0.4	49
363	Can Patients be Accurately Assessed for Familial Hypercholesterolaemia in Primary Care?. Heart Lung and Circulation, 2014, 23, 1153-1157.	0.4	24
364	Atorvastatin plus omegaâ€3 fatty acid ethyl ester decreases veryâ€lowâ€density lipoprotein triglyceride production in insulin resistant obese men. Diabetes, Obesity and Metabolism, 2014, 16, 519-526.	4.4	11
365	The doctor's dilemma: Challenges in the diagnosis and care of homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 542-549.	1.5	17
366	Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. Diabetes Research and Clinical Practice, 2014, 106, 328-336.	2.8	12
367	Association between skeletal muscle fat content and veryâ€lowâ€density lipoproteinâ€apolipoprotein Bâ€100 transport in obesity: effect of weight loss. Diabetes, Obesity and Metabolism, 2014, 16, 994-1000.	4.4	9
368	Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?. Expert Opinion on Drug Safety, 2014, 13, 1227-1239.	2.4	37
369	Inadequate fruit and vegetable intake in people with psychosis. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1025-1035.	2.3	40
370	More data needed on curcuminoids in hypertriglyceridaemia. Nature Reviews Cardiology, 2014, 11, 123-123.	13.7	0
371	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. Journal of the American College of Cardiology, 2014, 63, 2541-2548.	2.8	465
372	Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis, 2014, 234, 469-472.	0.8	27
373	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. Journal of Clinical Lipidology, 2014, 8, 148-172.	1.5	98
374	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. Contemporary Diabetes, 2014, , 239-278.	0.0	0
375	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. Journal of Clinical Lipidology, 2014, 8, 29-60.	1.5	289
376	Plasma Apolipoprotein B-48 Transport in Obese Men: A New Tracer Kinetic Study in the Postprandial State. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E122-E126.	3.6	32
377	Response to Familial Hypercholesterolemia: An Underâ€recognized but Significant Concern in Cardiology Practice Foody JM et al. Clin Cardiol. doi: 10.1002/clc.22223.. Clinical Cardiology, 2014, 37, 386-387.	1.8	5
378	Role of selective peroxisome proliferatorâ€activated receptor modulators in managing cardiometabolic disease: tale of a rollerâ€coaster. Diabetes, Obesity and Metabolism, 2014, 16, 780-792.	4.4	19

#	Article	IF	Citations
379	Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia. Journal of Clinical Lipidology, 2014, 8, 390-400.	1.5	149
380	Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipid Research, 2014, 56, 47-66.	11.6	128
381	New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2014, 15, 493-503.	1.8	150
382	The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 369-385.	4.7	32
383	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. Atherosclerosis, 2014, 232, 410-413.	0.8	36
384	Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis. Metabolism: Clinical and Experimental, 2014, 63, 1071-1077.	3.4	11
385	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 387-403.	4.7	30
386	Familial hypercholesterolemia in China: Prevalence and evidence of underdetection and undertreatment in a community population. International Journal of Cardiology, 2014, 174, 834-836.	1.7	82
387	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. International Journal of Cardiology, 2014, 171, 309-325.	1.7	316
388	Familial Hypercholesterolaemia in Primary Care: Knowledge and Practices among General Practitioners in Western Australia. Heart Lung and Circulation, 2014, 23, 309-313.	0.4	50
389	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes and Endocrinology,the, 2014, 2, 655-666.	11.4	473
390	Critical review of non-statin treatments for dyslipoproteinemia. Expert Review of Cardiovascular Therapy, 2014, 12, 359-371.	1.5	6
391	Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World Journal of Diabetes, 2014, 5, 165.	3.5	16
392	The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies. International Journal of Cardiology, 2013, 168, 1811-1818.	1.7	33
393	New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?. Cardiovascular Drugs and Therapy, 2013, 27, 559-567.	2.6	133
394	Fibrate therapy and circulating adiponectin concentrations: AÂsystematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis, 2013, 230, 110-120.	0.8	37
395	New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes. Clinical Therapeutics, 2013, 35, 1082-1098.	2.5	134
396	Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology, 2013, 10, 648-661.	13.7	92

#	Article	IF	Citations
397	Role of international registries in enhancing the care of familial hypercholesterolaemia. International Journal of Evidence-Based Healthcare, 2013, 11, 134-139.	0.5	28
398	PANACEA or much a do about nothing: Effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndrome. Atherosclerosis, 2013, 227, 32-34.	0.8	0
399	Impact of interpretative commenting on lipid profiles in people at high risk of familial hypercholesterolaemia. Clinica Chimica Acta, 2013, 422, 21-25.	1.1	33
400	Through the ophthalmoscope: New insight into the risk of cardiovascular disease in sleep disordered breathing?. Atherosclerosis, 2013, 226, 40-42.	0.8	0
401	Shared and distinct transcriptional programs underlie the hybrid nature of iNKT cells. Nature Immunology, 2013, 14, 90-99.	14.5	106
402	Novel Insights Into the Regulation of Postprandial Lipemia by Glucagon-Like Peptides: Significance for Diabetes. Diabetes, 2013, 62, 336-338.	0.6	6
403	A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. International Journal of Cardiology, 2013, 167, 2391-2396.	1.7	62
404	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 2013, 34, 3478-3490.	2.2	2,132
405	Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. Clinical Science, 2013, 125, 45-51.	4.3	17
406	Fenofibrate Inhibits Endothelin-1 Expression by Peroxisome Proliferatorâ€“Activated Receptor Î±â€“Dependent and Independent Mechanisms in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 621-628.	2.4	28
407	Dietary fatty acids and lipoprotein metabolism. Current Opinion in Lipidology, 2013, 24, 192-197.	2.7	43
408	Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment. Review of Diabetic Studies, 2013, 10, 133-156.	1.3	104
409	Supplementation with n3 Fatty Acid Ethyl Esters Increases Large and Small Artery Elasticity in Obese Adults on a Weight Loss Diet. Journal of Nutrition, 2013, 143, 437-441.	2.9	17
410	Thought for food: Clinical evidence for the dietary prevention strategy in cardiovascular disease. International Journal of Evidence-Based Healthcare, 2013, 11, 330-336.	0.5	7
411	Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care. Journal of Paediatrics and Child Health, 2013, 49, E263-72.	0.8	24
412	Insulin Resistance and the Metabolic Syndrome Are Associated With Arterial Stiffness in Patients With Chronic Kidney Disease. American Journal of Hypertension, 2013, 26, 1155-1161.	2.0	22
413	Familial hypercholesterolaemia in Australia: new insights and developments. Medical Journal of Australia, 2013, 198, 72-73.	1.7	2
414	Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender. PLoS ONE, 2013, 8, e82606.	2.5	41

#	Article	IF	Citations
415	Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes: Recent Clinical Trials. Review of Diabetic Studies, 2013, 10, 191-203.	1.3	11
416	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Annals of Clinical Biochemistry, 2012, 49, 534-537.	1.6	51
417	Postprandial dyslipidaemia and diabetes. Current Opinion in Lipidology, 2012, 23, 303-309.	2.7	21
418	Apolipoprotein B-100 and ApoA-II Kinetics as Determinants of Cellular Cholesterol Efflux. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1658-E1666.	3.6	22
419	Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012, 46, 753-761.	2.3	166
420	Screening for familial hypercholesterolaemia. Pathology, 2012, 44, 122-128.	0.6	27
421	Balancing the cardiometabolic benefits and risks of statins. Lancet, The, 2012, 380, 541-543.	13.7	9
422	Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. International Journal of Evidence-Based Healthcare, 2012, 10, 211-221.	0.5	25
423	Into the future: diversifying lipid management. Lancet, The, 2012, 380, 1971-1974.	13.7	6
424	Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: Effect of fenofibrate treatment. Atherosclerosis, 2012, 221, 484-489.	0.8	25
425	HSV-2 and atherosclerosis: Adding to the alphabet soup of coronary risk in HIV infection. Atherosclerosis, 2012, 223, 278-279.	0.8	0
426	Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 2012, 224, 430-434.	0.8	61
427	Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. Annals of Medicine, 2012, 44, 313-324.	3.8	35
428	Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3956-3964.	3.6	523
429	Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome. Journal of Lipid Research, 2012, 53, 2443-2449.	4.2	15
430	INTERIM Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia. Heart Lung and Circulation, 2012, 21, 159-162.	0.4	11
431	A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?. Heart Lung and Circulation, 2012, 21, 543-550.	0.4	16
432	Screening for lipid disorders. Pathology, 2012, 44, 115-121.	0.6	4

#	Article	IF	Citations
433	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vascular Health and Risk Management, 2012, 8, 651.	2.3	43
434	Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?. International Journal of Clinical Pharmacy, 2012, 34, 501-505.	2.1	12
435	Prevalence and predictors of abnormal arterial function in statin-treated type 2 diabetes mellitus patients. Metabolism: Clinical and Experimental, 2012, 61, 349-357.	3.4	5
436	Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism: Clinical and Experimental, 2012, 61, 3-11.	3.4	23
437	A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. Clinical Biochemist Reviews, 2012, 33, 25-31.	3.3	13
438	Detecting familial hypercholesterolaemia in general practice. Australian Family Physician, 2012, 41, 965-8.	0.5	21
439	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal, 2011, 32, 1345-1361.	2.2	993
440	Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart, 2011, 97, 350-356.	2.9	87
441	Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Postgraduate Medical Journal, 2011, 87, 776-782.	1.8	8
442	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
443	Altered metabolism of apolipoprotein C-III: a contributor in chronic kidney disease?. Clinical Lipidology, 2011, 6, 247-251.	0.4	0
444	Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men. Metabolism: Clinical and Experimental, 2011, 60, 1482-1487.	3.4	10
445	Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial. Cardiovascular Diabetology, 2011, 10, 102.	6.8	42
446	Coenzyme Q₁₀, endothelial function, and cardiovascular disease. BioFactors, 2011, 37, 366-373.	5.4	47
447	Hypertriglyceridaemia in statinâ€treated type 2 diabetic patients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 257-260.	0.2	2
448	Effect of laparoscopic sleeve gastrectomy on elevated C-reactive protein and atherogenic dyslipidemia in morbidly obese patients. Clinical Biochemistry, 2011, 44, 342-344.	1.9	23
449	Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 3543-3549.	0.7	26
450	Mechanism of Action of a Peroxisome Proliferator-Activated Receptor (PPAR)-Î´ Agonist on Lipoprotein Metabolism in Dyslipidemic Subjects with Central Obesity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1568-E1576.	3.6	68

#	Article	IF	Citations
451	Whither the Lipid Profile: Feast, Famine, or No Free Lunch?. Clinical Chemistry, 2011, 57, 363-365.	3.2	8
452	Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?. Expert Review of Cardiovascular Therapy, 2011, 9, 987-997.	1.5	6
453	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opinion on Pharmacotherapy, 2011, 12, 13-30.	1.8	59
454	Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. Journal of Lipid Research, 2011, 52, 794-800.	4.2	53
455	Nutrition and metabolism: new studies of the effects of diets and exercise on lipid and lipoprotein metabolism. Current Opinion in Lipidology, 2010, 21, 91-92.	2.7	1
456	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. Obstetrical and Gynecological Survey, 2010, 65, 175-176.	0.4	1
457	Nutrition and metabolism: nutritional therapy for disordered triglyceride metabolism and nonalcoholic fatty liver disease. Current Opinion in Lipidology, 2010, 21, 545-547.	2.7	6
458	Genetic determinants of apolipoprotein B-100 kinetics. Current Opinion in Lipidology, 2010, 21, 141-147.	2.7	5
459	Effects of atorvastatin and nâˆ’3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. American Journal of Clinical Nutrition, 2010, 91, 900-906.	4.7	25
460	Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. Clinical Science, 2010, 118, 79-85.	4.3	15
461	Regulation of plasma LDL: the apoB paradigm. Clinical Science, 2010, 118, 333-339.	4.3	49
462	Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated TypeÂ2 diabetic patients. Clinical Science, 2010, 118, 607-615.	4.3	37
463	More than meets the eye: the ACCORD trial and use of statinâ€fibrate combination in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2010, 27, 326-328.	0.2	0
464	The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.. Clinical Endocrinology, 2010, 73, no-no.	2.4	1
465	Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and veryâ€lowâ€density lipoprotein particle concentrations in statinâ€treated type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2010, 12, 752-756.	4.4	32
466	Family history: the neglected risk factor in disease prevention. Medical Journal of Australia, 2010, 193, 429-430.	1.7	4
467	Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal, 2010, 31, 2844-2853.	2.2	1,392
468	Nonalcoholic Fatty Liver Disease as the Transducer of Hepatic Oversecretion of Very-Low-Density Lipoproteinâ€“Apolipoprotein B-100 in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1043-1050.	2.4	52

#	Article	IF	Citations
469	Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet. Diabetes Care, 2010, 33, 1134-1139.	8.6	145
470	Early Recycling Compartment Trafficking of CD1a Is Essential for Its Intersection and Presentation of Lipid Antigens. Journal of Immunology, 2010, 184, 1235-1241.	0.8	35
471	Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diabetes and Vascular Disease Research, 2010, 7, 296-299.	2.0	26
472	On Reducing Cardiovascular Disease to a Rarity: Clinical Strategies and their Cost-Effectiveness. Heart Lung and Circulation, 2010, 19, 225-227.	0.4	0
473	A New Model of Care for Familial Hypercholesterolaemia from Western Australia: Closing a Major Gap in Preventive Cardiology. Heart Lung and Circulation, 2010, 19, 419-422.	0.4	22
474	Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. Atherosclerosis, 2010, 210, 326-330.	0.8	27
475	Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Atherosclerosis Supplements, 2010, 11, 61-64.	1.2	7
476	Progress in understanding postprandial dyslipidaemia: Second International Symposium on the Role of Chylomicrons in Disease I. Atherosclerosis Supplements, 2010, 11, 1-2.	1.2	1
477	Therapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome. , 2010, , 157-163.		0
478	Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?. Clinical Chemistry, 2009, 55, 2049-2052.	3.2	63
479	Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 810-812.	8.6	104
480	Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 989-997.	3.6	62
481	Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. Journal of Lipid Research, 2009, 50, 2524-2531.	4.2	62
482	Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome. Diabetes Care, 2009, 32, 2111-2113.	8.6	16
483	Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. , 2009, 123, 281-291.		27
484	Dissociation of endothelial function and arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2009, 71, 808-814.	2.4	33
485	Severe HDL deficiency due to novel defects in the ABCA1 transporter. Journal of Internal Medicine, 2009, 265, 359-372.	6.0	24
486	Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetes. Diabetes Research and Clinical Practice, 2009, 85, 310-316.	2.8	28

#	Article	IF	Citations
487	NICE Guidance on Familial Hypercholesterolaemia: All Sugar and Spice?. Heart Lung and Circulation, 2009, 18, 181-183.	0.4	3
488	Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3842-3848.	3.6	164
489	Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opinion on Pharmacotherapy, 2009, 10, 2973-2985.	1.8	114
490	The effects of Ï‰3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. Journal of Hypertension, 2009, 27, 1863-1872.	0.5	87
491	LDL apheresis for familial hypercholesterolemia: value, indications and demand. Clinical Lipidology, 2009, 4, 129-131.	0.4	3
492	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. International Journal of Clinical Practice, 2008, 62, 799-809.	1.7	62
493	Variation in Niemannâ€“Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clinical Endocrinology, 2008, 69, 45-51.	2.4	16
494	Effect of weight loss on markers of triglycerideâ€rich lipoprotein metabolism in the metabolic syndrome. European Journal of Clinical Investigation, 2008, 38, 743-751.	3.4	56
495	Detection of Familial Hypercholesterolaemia: A Major Treatment Gap in Preventative Cardiology. Heart Lung and Circulation, 2008, 17, 411-413.	0.4	39
496	Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thrombosis Research, 2008, 123, 374-380.	1.7	78
497	Polymorphism in postinsulin receptor signaling pathway is not associated with polycystic ovary syndrome. Fertility and Sterility, 2008, 90, 2298-2303.	1.0	4
498	Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Atherosclerosis, 2008, 197, 139-146.	0.8	38
499	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis, 2008, 196, 823-834.	0.8	57
500	Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis, 2008, 197, 732-739.	0.8	42
501	Chylomicrons in disease: A renaissance in lipidology. Atherosclerosis Supplements, 2008, 9, 1-2.	1.2	2
502	Dose-Dependent Effect of Rosuvastatin on VLDLâ€“Apolipoprotein C-III Kinetics in the Metabolic Syndrome. Diabetes Care, 2008, 31, 1656-1661.	8.6	36
503	Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction. Diabetes Care, 2008, 31, 1502-1509.	8.6	63
504	Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1831-1837.	2.4	49

#	Article	IF	Citations
505	Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Human Reproduction, 2008, 23, 2352-2358.	0.9	109
506	Estimating LDL ApoB: Infomania or Clinical Advance?. Clinical Chemistry, 2008, 54, 782-784.	3.2	2
507	Familial lipoprotein lipase deficiency caused by known (G188E) and novel (W394X) LPL gene mutations. Annals of Clinical Biochemistry, 2008, 45, 102-105.	1.6	15
508	Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States. Current Vascular Pharmacology, 2008, 6, 67-77.	1.7	8
509	Of Mice and Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1892-1895.	2.4	21
510	Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 557-564.	3.6	62
511	Dose-Dependent Regulation of High-Density Lipoprotein Metabolism with Rosuvastatin in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 430-437.	3.6	44
512	Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science, 2008, 114, 611-624.	4.3	225
513	Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. Clinical Science, 2008, 114, 543-545.	4.3	36
514	Nutrition and metabolism: non-alcoholic fatty liver disease â€“ pathogenesis, cardiovascular risk and therapy. Current Opinion in Lipidology, 2008, 19, 92-94.	2.7	7
515	HDL metabolism in context: looking on the bright side. Current Opinion in Lipidology, 2008, 19, 395-404.	2.7	24
516	The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. Current Opinion in Lipidology, 2008, 19, 592-599.	2.7	6
517	Nutrition and metabolism: new insights into lifestyle modifications and pharmacotherapy for managing cardiometabolic risk. Current Opinion in Lipidology, 2008, 19, 617-619.	2.7	1
518	Effect of Weight Loss on LDL and HDL Kinetics in the Metabolic Syndrome. Diabetes Care, 2007, 30, 2945-2950.	8.6	90
519	Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 404-405.	3.3	38
520	Metabolic Risk Factors for Vascular Disease in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 190-195.	5.6	212
521	The erectileâ€“endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 263-273.	3.3	55
522	Polymorphism of the follistatin gene in polycystic ovary syndrome. Molecular Human Reproduction, 2007, 13, 237-241.	2.8	36

#	Article	IF	Citations
523	Statins and Metabolism of High Density Lipoprotein. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 215-221.	1.0	20
524	Erectile dysfunction predicts generalised cardiovascular disease: Evidence from a caseâ€“control study. Atherosclerosis, 2007, 194, 458-464.	0.8	38
525	Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2007, 4, 89-102.	2.0	76
526	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. Expert Opinion on Therapeutic Targets, 2007, 11, 181-189.	3.4	54
527	Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension, 2007, 21, 297-306.	2.2	206
528	Revisiting the metabolic syndrome. Medical Journal of Australia, 2007, 187, 61-61.	1.7	0
529	Carotid intima-medial thickness measured on multiple ultrasound frames: evaluation of a DICOM-based software system. Cardiovascular Ultrasound, 2007, 5, 29.	1.6	37
530	A national diabetic ketoacidosis protocol: catches for the unwary?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 230-230.	0.2	0
531	Differences in plasma PLTP activity assays: constant or random error?. Clinical Endocrinology, 2007, 67, 317-317.	2.4	1
532	A Randomized Trial of the Effect of Statin and Fibrate Therapy on Arterial Function in CKD. American Journal of Kidney Diseases, 2007, 49, 776-785.	1.9	49
533	Metabolic syndrome and cardiometabolic risk in PCOS. Current Diabetes Reports, 2007, 7, 66-73.	4.2	28
534	Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome. Asia Pacific Journal of Clinical Nutrition, 2007, 16, 624-31.	0.4	20
535	New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents, 2006, 16, 349-361.	5.0	0
536	Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives. Atherosclerosis, 2006, 185, 227-239.	0.8	137
537	Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertility and Sterility, 2006, 86, 1438-1446.	1.0	28
538	Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm microcirculation in Type 2 diabetes: Associations with blood pressure and HDL cholesterol. Diabetes Research and Clinical Practice, 2006, 71, 59-67.	2.8	20
539	Revisiting the metabolic syndrome. Medical Journal of Australia, 2006, 185, 445-449.	1.7	67
540	Factorial study of the effect of nâ€“3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. American Journal of Clinical Nutrition, 2006, 84, 37-43.	4.7	91

#	Article	IF	Citations
541	Diabetes and the Kidney. , 2006, , 21-47.		1
542	Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clinical Science, 2006, 111, 193-199.	4.3	28
543	Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Current Opinion in Lipidology, 2006, 17, 28-36.	2.7	53
544	FISH OILS, PHYTOSTEROLS AND WEIGHT LOSS IN THE REGULATION OF LIPOPROTEIN TRANSPORT IN THE METABOLIC SYNDROME: LESSONS FROM STABLE ISOTOPE TRACER STUDIES. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 877-882.	1.9	13
545	Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes, Obesity and Metabolism, 2006, 8, 698-702.	4.4	50
546	Plasma phospholipid transfer protein activity, a determinant of HDL kineticsinÂvivo. Clinical Endocrinology, 2006, 65, 752-759.	2.4	5
547	Effect of an acute hyperinsulinaemic clamp on post-prandial lipaemia in subjects with insulin resistance. European Journal of Clinical Investigation, 2006, 36, 489-496.	3.4	11
548	High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. European Journal of Clinical Investigation, 2006, 36, 626-632.	3.4	5
549	Insulin Resistance, Inflammation, and Blood Pressure Determine Vascular Dysfunction in CKD. American Journal of Kidney Diseases, 2006, 48, 926-934.	1.9	74
550	Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma. Journal of Lipid Research, 2006, 47, 1274-1280.	4.2	21
551	High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 973-979.	3.6	54
552	Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 590-596.	2.4	72
553	Thematic review series: Patient-Oriented Research. Design and analysis of lipoprotein tracer kinetics studies in humans. Journal of Lipid Research, 2006, 47, 1607-1619.	4.2	55
554	Recent advances in the investigation of lipoprotein metabolism using tracer methodology. Clinical Laboratory, 2006, 52, 353-61.	0.5	3
555	The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes, Obesity and Metabolism, 2005, 7, 381-389.	4.4	32
556	Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes, Obesity and Metabolism, 2005, 7, 406-413.	4.4	125
557	Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes. Diabetes, Obesity and Metabolism, 2005, 7, 612-617.	4.4	34
558	Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria. Diabetic Medicine, 2005, 22, 239-242.	2.3	77

#	Article	IF	Citations
559	Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy. Diabetic Medicine, 2005, 22, 1558-1565.	2.3	26
560	Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?. Clinical Endocrinology, 2005, 63, 650-656.	2.4	5
561	Highâ€density Lipoprotein Apolipoprotein Aâ€I Kinetics in Obesity. Obesity, 2005, 13, 1008-1016.	4.0	42
562	Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Clinical Biochemistry, 2005, 38, 806-812.	1.9	7
563	Metabolic and cardiovascular risk in the polycystic ovary syndrome. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2005, 22, 261-265.	0.2	2
564	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 183, 222-223.	1.7	0
565	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-553.	1.7	19
566	Adipocytokines and VLDL Metabolism: Independent Regulatory Effects of Adiponectin, Insulin Resistance, and Fat Compartments on VLDL Apolipoprotein B-100 Kinetics?. Diabetes, 2005, 54, 795-802.	0.6	105
567	Adiponectin and other Adipocytokines as Predictors of Markers of Triglyceride-Rich Lipoprotein Metabolism. Clinical Chemistry, 2005, 51, 578-585.	3.2	93
568	NDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24. Biochemical and Biophysical Research Communications, 2005, 332, 982-992.	2.1	36
569	Assessment of central and peripheral arterial stiffnessStudies indicating the need to use a combination of techniques. American Journal of Hypertension, 2005, 18, 249-260.	2.0	123
570	Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs, 2005, 65, 31-74.	10.9	66
571	Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?. European Heart Journal, 2004, 25, 716-719.	2.2	1
572	Regulation of Endothelial Nitric Oxide Synthase by PPAR Agonists: Molecular and Clinical Perspectives. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 619-621.	2.4	12
573	ATP-Binding Cassette Transporter G8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2188-2191.	2.4	28
574	Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 537-548.	0.5	105
575	Reduced forearm reactive hyperaemia in normoalbuminuric subjects with Type 1 diabetes and retinopathy. Diabetic Medicine, 2004, 21, 931-935.	2.3	6
576	LDL heterogeneity revisited: lesson for the metabolic syndrome from a new interpopulation study?. European Journal of Clinical Investigation, 2004, 34, 719-722.	3.4	10

#	Article	IF	Citations
577	Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs, 2004, 4, 227-246.	2.2	94
578	Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men. Diabetes Research and Clinical Practice, 2004, 63, 77-85.	2.8	22
579	Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. Annals of Epidemiology, 2004, 14, 627-632.	1.9	29
580	Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation, 2004, 2, 3-34.	0.0	5
581	Cardiovascular risk factors and endothelial dysfunction. Clinical Science, 2004, 107, 609-615.	4.3	31
582	Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Clinical Science, 2004, 107, 221-232.	4.3	42
583	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clinical Science, 2004, 107, 233-249.	4.3	42
584	Dyslipidemia in the metabolic syndrome. Journal of Drug Evaluation, 2004, 2, 3-34.	0.0	3
585	Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clinical Biochemist Reviews, 2004, 25, 31-48.	3.3	7
586	HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease. Clinical Biochemist Reviews, 2004, 25, 7-18.	3.3	6
587	Identification of Lipoproteins of Intestinal Origin in Human Atherosclerotic Plaque. Clinical Chemistry and Laboratory Medicine, 2003, 41, 792-5.	2.3	90
588	Can coenzyme Q₁₀ improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. BioFactors, 2003, 18, 129-136.	5.4	29
589	Comparison of intraperitoneal and posterior subcutaneous abdominal adipose tissue compartments as predictors of VLDL apolipoprotein B-100 kinetics in overweight/obese men. Diabetes, Obesity and Metabolism, 2003, 5, 202-206.	4.4	5
590	Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without typeÂ2 diabetes mellitus. Clinical Endocrinology, 2003, 58, 415-420.	2.4	37
591	Measuring arterial stiffness in diabetic patients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2003, 20, 25-30.	0.2	1
592	Earlier insulin therapy for type 2 diabetes: striving for cost-effectiveness. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2003, 20, 45-46.	0.2	1
593	Fat Compartments and Apolipoprotein Bâ€100 Kinetics in Overweightâ€Obese Men. Obesity, 2003, 11, 152-159.	4.0	18
594	Plasma Markers of Cholesterol Homeostasis and Apolipoprotein Bâ€100 Kinetics in the Metabolic Syndrome. Obesity, 2003, 11, 591-596.	4.0	27

#	Article	IF	Citations
595	Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome. International Journal of Obesity, 2003, 27, 862-865.	3.4	47
596	Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis, 2003, 166, 85-93.	0.8	172
597	Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis, 2003, 168, 169-179.	0.8	85
598	Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. International Immunology, 2003, 15, 915-925.	4.0	126
599	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism: Clinical and Experimental, 2003, 52, 1279-1286.	3.4	29
600	Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism: Clinical and Experimental, 2003, 52, 136-141.	3.4	50
601	Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome. Diabetes, 2003, 52, 803-811.	0.6	207
602	Effects of exercise training on conduit and resistance vessel function in treated and untreated hypercholesterolaemic subjects. European Heart Journal, 2003, 24, 1681-1689.	2.2	67
603	Docosahexaenoic Acid But Not Eicosapentaenoic Acid Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients. Diabetes Care, 2003, 26, 253-253.	8.6	60
604	Waist circumference, waist-to-hip ratio and body mass index as predictors of adipose tissue compartments in men. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 441-447.	0.5	198
605	The Effect of Alcohol Intake on Insulin Sensitivity in Men: A randomized controlled trial. Diabetes Care, 2003, 26, 608-612.	8.6	54
606	Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 825-832.	0.5	62
607	Effects of alcohol intake on endothelial function in men. Journal of Hypertension, 2003, 21, 97-103.	0.5	42
608	Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Current Opinion in Lipidology, 2003, 14, 61-68.	2.7	27
609	Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clinical Science, 2003, 104, 383-388.	4.3	27
610	Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clinical Science, 2003, 104, 383.	4.3	32
611	Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. Clinical Science, 2003, 105, 537-540.	4.3	34
612	Randomized controlled trial of the effect of nâ€“3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. American Journal of Clinical Nutrition, 2003, 77, 300-307.	4.7	165

#	Article	IF	Citations
613	Measurement and application of arterial stiffness in clinical research: focus on new methodologies and diabetes mellitus. Medical Science Monitor, 2003, 9, RA81-9.	1.1	35
614	Postischemic Microcirculatory Blood Flow Correlates Negatively and Independently With Plasma C-Reactive Protein in Longstanding Type 1 Diabetes. Diabetes Care, 2002, 25, 802-803.	8.6	4
615	Conservation of CD1 Intracellular Trafficking Patterns Between Mammalian Species. Journal of Immunology, 2002, 169, 6951-6958.	0.8	22
616	Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2283-2289.	3.6	43
617	Regular ingestion of black tea improves brachial artery vasodilator function. Clinical Science, 2002, 102, 195-201.	4.3	105
618	The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. Clinical Science, 2002, 103, 595-597.	4.3	18
619	Regular ingestion of black tea improves brachial artery vasodilator function. Clinical Science, 2002, 102, 195.	4.3	92
620	Insulin resistance, dyslipidaemia, inflammation and endothelial function in nephrotic syndrome. Nephrology Dialysis Transplantation, 2002, 17, 2220-2225.	0.7	45
621	Leukocyte count and vascular function in Type 2 diabetic subjects with treated hypertension. Atherosclerosis, 2002, 163, 175-181.	0.8	39
622	Regulatory Effects of HMG CoA Reductase Inhibitor and Fish Oils on Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Male Subjects With Dyslipidemia. Diabetes, 2002, 51, 2377-2386.	0.6	162
623	Influence of an asparagine to lysine mutation at amino acid 3516 of apolipoprotein B on low-density lipoprotein receptor binding. Clinica Chimica Acta, 2002, 321, 113-121.	1.1	14
624	Shifting the LDL-receptor paradigm in familial hypercholesterolemia: novel insights from recent kinetic studies of apolipoprotein B-100 metabolism. Atherosclerosis Supplements, 2002, 2, 1-4.	1.2	9
625	Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration. Metabolism: Clinical and Experimental, 2002, 51, 1041-1046.	3.4	129
626	Adipose tissue compartments and the kinetics of very[ndash]low-density lipoprotein apolipoprotein B-100 in non-obese men. Metabolism: Clinical and Experimental, 2002, 51, 1206-1210.	3.4	7
627	Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity. Clinical Chemistry, 2002, 48, 278-283.	3.2	109
628	Effect of Atorvastatin and Fish Oil on Plasma High-Sensitivity C-Reactive Protein Concentrations in Individuals with Visceral Obesity. Clinical Chemistry, 2002, 48, 877-883.	3.2	129
629	Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension,,. American Journal of Clinical Nutrition, 2002, 76, 1007-1015.	4.7	296
630	Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. American Journal of Cardiology, 2002, 90, 1254-1257.	1.6	76

#	Article	IF	Citations
631	Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia, 2002, 45, 420-426.	6.3	180
632	Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney International, 2002, 62, 550-557.	5.2	45
633	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. European Journal of Clinical Investigation, 2002, 32, 429-436.	3.4	82
634	Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia. European Journal of Clinical Investigation, 2002, 32, 493-499.	3.4	10
635	Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition, 2002, 56, 1137-1142.	2.9	225
636	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-712.	4.2	37
637	Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. Journal of Lipid Research, 2002, 43, 344-349.	4.2	32
638	Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clinical Chemistry, 2002, 48, 278-83.	3.2	21
639	Oxazolinone derivative of leucine for GC-MS: a sensitive and robust method for stable isotope kinetic studies of lipoproteins. Journal of Lipid Research, 2002, 43, 344-9.	4.2	30
640	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-12.	4.2	30
641	Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. Atherosclerosis, 2001, 157, 519-523.	0.8	23
642	HDL kinetics, fish oils and diabetes. Atherosclerosis, 2001, 159, 243-244.	0.8	1
643	Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clinica Chimica Acta, 2001, 306, 63-69.	1.1	26
644	Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E626-E632.	3.5	90
645	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. Medical Journal of Australia, 2001, 174, 611-611.	1.7	0
646	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. Medical Journal of Australia, 2001, 174, 66-67.	1.7	4
647	Homocysteine and nephrotic syndrome. Nephrology Dialysis Transplantation, 2001, 16, 1720-1721.	0.7	9
648	Diet, obesity and endothelial dysfunction: of rats and men. Clinical Science, 2001, 101, 345-347.	4.3	1

#	Article	IF	Citations
649	Diet, obesity and endothelial dysfunction: of rats and men. Clinical Science, 2001, 101, 345.	4.3	0
650	Endothelium-dependent and independent vasodilation studied at normoglycaemia in Type I diabetes mellitus with and without microalbuminuria. Diabetologia, 2001, 44, 593-601.	6.3	139
651	Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. , 2001, 2, 118.		17
652	Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. European Journal of Clinical Investigation, 2001, 31, 113-117.	3.4	36
653	Vascular function of the peripheral circulation in patients with nephrosis. Kidney International, 2001, 60, 182-189.	5.2	37
654	Therapeutic considerations for postprandial dyslipidaemia. Diabetes, Obesity and Metabolism, 2001, 3, 143-156.	4.4	7
655	Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von) Tj ETQq1 1 0.784314 rgBT /Over	3.6	7
656	Oxidant stress in nephrotic syndrome: comparison of F2â€isoprostanes and plasma antioxidant potential. Nephrology Dialysis Transplantation, 2001, 16, 1626-1630.	0.7	36
657	Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. American Journal of Clinical Nutrition, 2000, 71, 1085-1094.	4.7	513
658	Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 54-59.	0.2	4
659	Genes and diabetic nephropathy: what have we learnt so far?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2000, 17, 84-90.	0.2	4
660	Endothelial dysfunction in Type 1 diabetes mellitus: methodological considerations. Diabetic Medicine, 2000, 17, 687-688.	2.3	0
661	Cardiovascular disease towards 2000: activities of the West Australian Heart Research Institute. Australian and New Zealand Journal of Medicine, 2000, 30, 236-240.	0.5	0
662	Câ€reactive protein: a new cardiovascular risk factor?. Medical Journal of Australia, 2000, 173, 117-118.	1.7	4
663	Sterol 27-Hydroxylase Acts on 7-Ketocholesterol in Human Atherosclerotic Lesions and Macrophages in Culture. Journal of Biological Chemistry, 2000, 275, 27627-27633.	3.4	75
664	Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Vascular Reactivity of the Forearm Microcirculation in Hyperlipidemic, Overweight Men. Circulation, 2000, 102, 1264-1269.	1.6	331
665	Kinetics of veryâ€"low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies. Metabolism: Clinical and Experimental, 2000, 49, 1204-1210.	3.4	29
666	Learning by doing â€" An exploration of experience, critical incidents and reflection in entrepreneurial learning. International Journal of Entrepreneurial Behaviour and Research, 2000, 6, 104-124.	3.8	566

#	Article	IF	Citations
667	Postprandial lipaemia in familial hypercholesterolaemia: clinical and metabolic significance. Atherosclerosis, 2000, 148, 426-428.	0.8	22
668	Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. European Journal of Clinical Investigation, 1999, 29, 204-209.	3.4	69
669	Endothelial dysfunction in Type 1 diabetic subjects with and without microalbuminuria. Diabetic Medicine, 1999, 16, 841-847.	2.3	74
670	Endothelial dysfunction, insulin resistance and diabetes: exploring the web of causality. Australian and New Zealand Journal of Medicine, 1999, 29, 523-534.	0.5	16
671	Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. American Journal of Clinical Nutrition, 1999, 70, 817-825.	4.7	253
672	Fibrates, dyslipoproteinaemia and cardiovascular disease. Current Opinion in Lipidology, 1999, 10, 561-574.	2.7	129
673	Reduction in Visceral Adipose Tissue Is Associated with Improvement in Apolipoprotein B-100 Metabolism in Obese Men. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2854-2861.	3.6	78
674	Postprandial dyslipidaemia in a nutshell: food for thought. Australian and New Zealand Journal of Medicine, 1998, 28, 816-823.	0.5	13
675	Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. International Journal of Obesity, 1998, 22, 414-423.	3.4	112
676	SPECIAL ARTICLE: NON-INVASIVE MEASUREMENT OF ENDOTHELIAL FUNCTION. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 640-643.	1.9	43
677	Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis, 1998, 141, 17-30.	0.8	102
678	Privatization and Company Restructuring in Eastern Europe. Journal of East-West Business, 1998, 4, 29-46.	0.7	1
679	Ansoffâ€™s Matrix, pain and gain. International Journal of Entrepreneurial Behaviour and Research, 1998, 4, 101-111.	3.8	54
680	Comparison of Urinary Albumin, Retinol-Binding Protein and N-Acetyl Î²-Glucosaminidase as Predictors of Progression of Low Level Albuminuria in Diabetes. Annals of Clinical Biochemistry, 1997, 34, 202-204.	1.6	3
681	Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man. Atherosclerosis, 1997, 135, 83-91.	0.8	17
682	Management of Lipid Disorders in the Elderly. Drugs and Aging, 1997, 10, 444-462.	2.7	13
683	Preserved Endothelial Function in Patients With Severe Hypertriglyceridemia and Low Functional Lipoprotein Lipase Activity. Journal of the American College of Cardiology, 1997, 29, 964-968.	2.8	86
684	Reply to PM Kris-Etherton et al. American Journal of Clinical Nutrition, 1997, 65, 1090.	4.7	0

#	Article	IF	Citations
685	DETERMINANTS OF THE KINETICS OF VERY LOW-DENSITY LIPOPROTEIN APOLIPOPROTEIN B-100 IN NON-OBESE MEN. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 556-562.	1.9	7
686	Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. , 1997, 14, 974-978.		69
687	Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. Human Mutation, 1997, 10, 465-473.	2.5	39
688	Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. Human Mutation, 1997, 10, 465-473.	2.5	4
689	Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes. Diabetes Research and Clinical Practice, 1996, 32, 81-90.	2.8	12
690	Apolipoprotein B independently predicts progression of veryâ€"low-level albuminuria in insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1996, 45, 1101-1107.	3.4	32
691	Dietary fatty acids and progression of coronary artery disease in men. American Journal of Clinical Nutrition, 1996, 64, 202-209.	4.7	103
692	Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Current Opinion in Lipidology, 1996, 7, 341-355.	2.7	40
693	Urinary Infection and Albumin Excretion in Insulin-dependent Diabetes Mellitus: Implications for the Measurement of Microalbuminuria. Diabetic Medicine, 1996, 13, 520-524.	2.3	15
694	Complete deficiency of plasma lecithin-cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (Gly-30-Ser) in the LCAT gene. Human Mutation, 1996, 8, 79-82.	2.5	11
695	Increased Hepatic Secretion of Very-Low-Density Lipoprotein Apolipoprotein B-100 in Obesity: A Stable Isotope Study. Clinical Science, 1995, 88, 225-233.	4.3	71
696	Simvastatin decreases the hepatic secretion of veryâ€lowâ€density lipoprotein apolipoprotein Bâ€100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. European Journal of Clinical Investigation, 1995, 25, 559-567.	3.4	47
697	von Willebrand factor, a possible indicator of endothelial cell damage, decreases during longâ€term compliance with a lipidâ€lowering diet. Journal of Internal Medicine, 1995, 237, 557-561.	6.0	30
698	Lecithinâ€cholesterol acyltransferase deficiency presenting with acute pancreatitis: effect of infusion of normal plasma on triglycerideâ€rich lipoproteins. Journal of Internal Medicine, 1995, 238, 137-141.	6.0	6
699	Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia, 1995, 38, 959-967.	6.3	119
700	Quantitative coronary cineangiography for the study of atherosclerosis. Medical Engineering and Physics, 1995, 17, 356-365.	1.7	6
701	Exercise Testing as a Long-Term Predictor of the Development of Microalbuminuria in Normoalbuminuric IDDM Patients. Diabetes Care, 1995, 18, 1602-1605.	8.6	18
702	Independent Correlation Between Plasma Lipoprotein(a) and Angiographie Coronary Artery Disease in NIDDM. Diabetes Care, 1995, 18, 234-236.	8.6	26

#	Article	IF	Citations
703	Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects. Metabolism: Clinical and Experimental, 1995, 44, 1052-1057.	3.4	56
704	The implications of the detection of proteinuria and microalbuminuria in insulin and nonâ€insulin dependent diabetes. Australian and New Zealand Journal of Medicine, 1995, 25, 157-161.	0.5	6
705	Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis, 1995, 113, 79-89.	0.8	64
706	Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease. Atherosclerosis, 1995, 114, 133-135.	0.8	11
707	Familial Hypercholesterolaemia Regression Study and its implications. Lancet, The, 1995, 345, 807-808.	13.7	4
708	Nutrient intake and progression of coronary artery disease. American Journal of Cardiology, 1994, 73, 328-332.	1.6	80
709	The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology, 1994, 41, 345-350.	2.4	140
710	Short-term effects of mepacrine on serum lipids, lipoproteins, and apolipoproteins in patients with non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1994, 43, 131-134.	3.4	4
711	Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet, The, 1994, 344, 305-306.	13.7	78
712	No Association Between Serum Platelet-derived Growth Factor, Platelet Size, and Regression of Angiographically-defined Coronary Artery Disease. Platelets, 1994, 5, 135-138.	2.3	2
713	Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism: Clinical and Experimental, 1993, 42, 415-419.	3.4	26
714	Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism: Clinical and Experimental, 1993, 42, 1519-1523.	3.4	237
715	Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism: Clinical and Experimental, 1993, 42, 1461-1467.	3.4	148
716	Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase. Atherosclerosis, 1993, 103, 231-243.	0.8	12
717	Human lymphocyte sodium-hydrogen exchange. The influences of lipids, membrane fluidity, and insulin.. Hypertension, 1993, 21, 344-352.	2.7	39
718	Decision support for the management of lipid disorders using Causal Probabilistic Networks: A development strategy. , 1992, , .		0
719	One year experience in the treatment of familial hypercholesterolaemia with simvastatin.. Postgraduate Medical Journal, 1992, 68, 575-580.	1.8	8
720	Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: A study in familial lipoprotein-lipase deficiency. Atherosclerosis, 1992, 95, 119-125.	0.8	96

#	Article	IF	Citations
721	Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet, The, 1992, 339, 563-569.	13.7	818
722	Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet, The, 1992, 340, 1430-1432.	13.7	459
723	Setting the standards for diabetes care: Microalbuminuria. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1992, 9, 84-86.	0.2	2
724	Management of patients with severe hypertriglyceridaemia during pregnancy: report of two cases with familial lipoprotein lipase deficiency. BJOG: an International Journal of Obstetrics and Gynaecology, 1992, 99, 163-166.	2.3	25
725	Comparison of the Realâ€time Use of Glycosylated Haemoglobin and Plasma Fructosamine in the Diabetic Clinic. Diabetic Medicine, 1991, 8, 573-579.	2.3	8
726	Effect of Ketones and Glucose on the Estimation of Urinary Creatinine: Implications for Microalbuminuria Screening. Diabetic Medicine, 1990, 7, 263-265.	2.3	5
727	Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring microalbuminuria. Diabetes Research and Clinical Practice, 1990, 9, 169-177.	2.8	21
728	Serum fructosamine and glycosylated haemoglobin in the monitoring of glycaemic control in insulin-dependent diabetic outpatients. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1989, 6, 159-162.	0.2	1
729	Serum fructosamine and HbA1. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1989, 6, 285-285.	0.2	0
730	An Acceptable Exercise Test to Study Microalbuminuria in Type 1 Diabetes. Diabetic Medicine, 1989, 6, 787-792.	2.3	12
731	Serum Lipids and Lipoproteins in Insulinâ€dependent Diabetic Patients with Persistent Microalbuminuria. Diabetic Medicine, 1989, 6, 25-30.	2.3	68
732	Quality assessment of visual test strips for home blood glucose monitoring. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1988, 5, 33-35.	0.2	0
733	Urinary albumin excretion in healthy adult subjects: Reference values and some factors affecting their interpretation. Clinica Chimica Acta, 1988, 172, 191-198.	1.1	95
734	Sideâ€room Tests to Screen for Microâ€albuminuria in Diabetes Mellitus. Diabetic Medicine, 1988, 5, 298-303.	2.3	12
735	The urinary excretion of albumin in normal pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 1987, 94, 408-412.	2.3	45
736	The use of random urine samples to screen for microalbuminuria in the diabetic clinic. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1986, 3, 86-88.	0.2	16
737	The skin in diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1986, 3, 196-199.	0.2	0
738	Filter paper spot blood glucose. Laboratory and patient methodology. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1985, 2, 41-44.	0.2	7